Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE:002907)
China · Delayed Price · Currency is CNY 13.00
-0.39 (-2.91%)
Nov 13, 2026, 3:04 PM CST
SHE:002907 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 838.36 | 815.21 | 764.14 | 680.84 | 774.72 | 837.23 |
Other Revenue | 11.93 | 11.93 | 10.68 | 10.7 | 10.47 | 8.91 |
| 850.29 | 827.14 | 774.82 | 691.54 | 785.18 | 846.14 | |
Revenue Growth | 8.11% | 6.75% | 12.04% | -11.93% | -7.20% | -4.12% |
Cost of Revenue | 375.74 | 353.96 | 332.91 | 312.45 | 320.55 | 400.53 |
Gross Profit | 474.56 | 473.18 | 441.91 | 379.1 | 464.63 | 445.61 |
Selling, General & Admin | 291.71 | 317.2 | 308.36 | 263.88 | 292.53 | 297.82 |
Research & Development | 82.02 | 89.76 | 59.13 | 78.12 | 58.82 | 41.72 |
Other Operating Expenses | 25.46 | 13.22 | 12.11 | 11.01 | 12.34 | 11.58 |
Operating Expenses | 403.64 | 420.38 | 381.01 | 351.31 | 367.04 | 350.65 |
Operating Income | 70.92 | 52.8 | 60.9 | 27.78 | 97.59 | 94.95 |
Interest Expense | -3.16 | -0.14 | - | -0.95 | -14.42 | -18.22 |
Interest & Investment Income | - | 14.79 | 10.32 | 9.81 | 11.5 | 16.4 |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | 0 | -0 | - | - |
Other Non Operating Income (Expenses) | 15.48 | -0.3 | 0.27 | -0.17 | -0.03 | -0.03 |
EBT Excluding Unusual Items | 83.26 | 67.17 | 71.49 | 36.48 | 94.64 | 93.11 |
Gain (Loss) on Sale of Investments | 1.82 | 1.42 | 1.38 | -4.67 | -2.61 | -1.33 |
Gain (Loss) on Sale of Assets | 11.7 | 10.25 | - | 0.06 | - | -0.01 |
Asset Writedown | -0.35 | -0.44 | -0.03 | -2.37 | -0.17 | - |
Other Unusual Items | 6.69 | -0.94 | 20.6 | 13.3 | 16.37 | 11.65 |
Pretax Income | 103.11 | 77.46 | 93.44 | 42.8 | 108.24 | 103.42 |
Income Tax Expense | 24.15 | 22.25 | 16.71 | 10.1 | 9.84 | 11.64 |
Earnings From Continuing Operations | 78.96 | 55.21 | 76.73 | 32.7 | 98.4 | 91.78 |
Minority Interest in Earnings | 14.88 | 9.88 | - | - | - | - |
Net Income | 93.83 | 65.09 | 76.73 | 32.7 | 98.4 | 91.78 |
Net Income to Common | 93.83 | 65.09 | 76.73 | 32.7 | 98.4 | 91.78 |
Net Income Growth | 25.77% | -15.17% | 134.66% | -66.77% | 7.21% | -22.99% |
Shares Outstanding (Basic) | 418 | 417 | 418 | 418 | 403 | 401 |
Shares Outstanding (Diluted) | 418 | 417 | 418 | 418 | 403 | 401 |
Shares Change | -0.05% | -0.05% | 0.02% | 3.60% | 0.49% | 0.06% |
EPS (Basic) | 0.22 | 0.16 | 0.18 | 0.08 | 0.24 | 0.23 |
EPS (Diluted) | 0.22 | 0.16 | 0.18 | 0.08 | 0.24 | 0.23 |
EPS Growth | 25.82% | -15.13% | 134.61% | -67.92% | 6.69% | -23.04% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 83.47 | 47.68 | 145.62 | 126.52 | -47.57 | 26.21 |
Free Cash Flow Per Share | 0.20 | 0.11 | 0.35 | 0.30 | -0.12 | 0.07 |
Dividend Per Share | 0.075 | 0.075 | 0.085 | 0.050 | 0.070 | 0.050 |
Dividend Growth | -11.77% | -11.77% | 70.00% | -28.57% | 40.00% | 78.57% |
Gross Margin | 55.81% | 57.21% | 57.03% | 54.82% | 59.17% | 52.66% |
Operating Margin | 8.34% | 6.38% | 7.86% | 4.02% | 12.43% | 11.22% |
Profit Margin | 11.04% | 7.87% | 9.90% | 4.73% | 12.53% | 10.85% |
Free Cash Flow Margin | 9.82% | 5.76% | 18.79% | 18.30% | -6.06% | 3.10% |
EBITDA | 155.75 | 138.5 | 147.74 | 109.68 | 172.13 | 164.7 |
EBITDA Margin | 18.32% | 16.74% | 19.07% | 15.86% | 21.92% | 19.46% |
D&A For EBITDA | 84.84 | 85.7 | 86.84 | 81.9 | 74.54 | 69.74 |
EBIT | 70.92 | 52.8 | 60.9 | 27.78 | 97.59 | 94.95 |
EBIT Margin | 8.34% | 6.38% | 7.86% | 4.02% | 12.43% | 11.22% |
Effective Tax Rate | 23.43% | 28.72% | 17.89% | 23.59% | 9.09% | 11.25% |
Revenue as Reported | 850.29 | 827.14 | 774.82 | 691.54 | 785.18 | 846.14 |